Liberty Global Ltd Class C vs Revvity Inc — how do they compare? Liberty Global Ltd Class C trades at $8.52 (market cap $3.06B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 5.5× Liberty Global Ltd Class C's market cap, and Revvity Inc pays a 0.18% dividend while Liberty Global Ltd Class C pays none. Which is the better fit depends on your goals — on Pluang, investors hold Liberty Global Ltd Class C for 21 Days and Revvity Inc for 12 Days on average.
| LBTYK | RVTY | |
|---|---|---|
Market Cap | $3.06B | $16.98B |
Volume | 2,508,956 | 1,456,900 |
Sector | Media | Health |
52-Week High | $12.67 | $157.36 |
52-Week Low | $8.52 | $82.26 |
Typical Hold Time | 21 Days | 12 Days |
Enterprise Value | $9.72B | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
LBTYK trades at $8.75, near its 52-week low, reflecting a bearish technical trend with weak moving averages and oscillators. Fundamentally, the company reported a net loss of -$7.14B in 2025 despite $4.88B in revenue, though 2026 shows improvement with a reduced loss of -$3.0B. Recent strategic moves include the Ziggo Group spin-off preparation and an AI partnership to enhance customer experience.
The stock presents a high-risk opportunity with a discounted valuation (P/S 0.61, P/B 0.32) and strong analyst support (69% buy ratings, $12.67 target). Key risks are persistent losses and execution challenges, but upside potential exists if Ziggo's 2027 listing and cost controls drive profitability.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →